coronary artery disease - revascularization with drug eluting stent - in stent restenosis clinical trials results meta-analysis

<h1> <a href="TM29-79-revascularization with drug eluting stent-coronary artery disease" > <strong>coronary artery disease</strong> - revascularization with drug eluting stent </a> - in stent restenosis trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t6543.htm"> SISR, 2007 </a> <br> NCT00231257 </td> <td> Sirolimus-eluting stents<br>  <i>versus</i> <br> brachytherapy </td> <td> restenosis within a bare metal stent </td> <td> follow-up 12 months<br> n=259/125<br> Parallel groups<br> open <br> US and Canadian </td> </tr> <tr> <td> <a href="../TRC_t6581.htm"> ISAR-DESIRE (SES vs PES), 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> In-stent restenosis. AP and/or positive test, previously stented, no AMI </td> <td> follow-up 1y<br> n=100/100<br> Parallel groups<br> open <br> germany </td> </tr> <tr> <td> <a href="../TRC_t6654.htm"> ISAR-DESIRE-2, 2010 </a> <br> NCT00598715 </td> <td> sirolimus-eluting stent<br>  <i>versus</i> <br> paclitaxel-eluting stent </td> <td> coronary restenosis in sirolimus-eluting stents </td> <td> follow-up 1y<br> n=225/225<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="../TRC_t8639.htm"> TAXUS V ISR, 2006 </a> <br> NCT00287573 </td> <td> TAXUS Express2<br>  <i>versus</i> <br> angioplasty followed by vascular brachytherapy with a beta source </td> <td> patients with restenotic lesions after prior stent implantation in native coronary arteries </td> <td> follow-up <br> n=195/201<br> Parallel groups<br> open <br> North America </td> </tr> <tr> <td> <a href="../TRC_t8806.htm"> RIBS-II, 2008 </a> <br> </td> <td> sirolimus-eluting stents<br>  <i>versus</i> <br> Balloon angioplasty </td> <td> patients with bare metal in-stent restenosis </td> <td> follow-up >1 year<br> n=76/74<br> Parallel groups<br> open <br> Spanish </td> </tr> <tr> <td> <a href="../TRC_t6629.htm"> CRISTAL, 0 </a> <br> NCT00323895 </td> <td> Cypher Select<br>  <i>versus</i> <br> Balloon Re-Angioplasty </td> <td> Intra-Des Restenosis. </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t6636.htm"> DES-ISR, 0 </a> <br> NCT00485030 </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> patients Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t6643.htm"> FOCUS, 0 </a> <br> NCT00485004 </td> <td> sirolimus-eluting implantation cypher<br>  <i>versus</i> <br> cutting balloon angioplasty </td> <td> focal in-stent restenosis after drug-eluting stent </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> </table> <h2>References</h2> <p> <b>SISR, 2007 : </b> Reynolds MR, Pinto DS, Shi C, Walczak J, Berezin R, Holmes DR, Cohen DJ, Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. <i>Am Heart J 2007;154:1221-7.</i> [PMID 18035097] 10.1016/j.ahj.2007.07.033 </p> <p> <b>SISR, 2007 : </b> Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SASirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. <i>JAMA 2006;295:1264-73</i> [PMID 16531619] </p> <p> <b>ISAR-DESIRE (SES vs PES), 2005 : </b> Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig ASirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. <i>JAMA 2005;293:165-71</i> [PMID 15644543] </p> <p> <b>ISAR-DESIRE-2, 2010 : </b> Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati ARandomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study. <i>J Am Coll Cardiol 2010 Mar 5;:</i> [PMID 20226618] 10.1016/j.jacc.2010.02.009 </p> <p> <b>TAXUS V ISR, 2006 : </b> Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell MEPaclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. <i>JAMA 2006 Mar 15;295:1253-63</i> [PMID 16531618] </p> <p> <b>TAXUS V ISR, 2006 : </b> Ellis SG, O'Shaughnessy CD, Martin SL, Kent K, McGarry T, Turco MA, Kereiakes DJ, Popma JJ, Friedman M, Koglin J, Stone GWTwo-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. <i>Eur Heart J 2008 Jul;29:1625-34</i> [PMID 18556716] </p> <p> <b>RIBS-II, 2008 : </b> Alfonso F, Pérez-Vizcayno MJ, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Iñiguez A, Morís C, Cequier A, Sabaté M, Escaned J, Jiménez-Quevedo P, Bañuelos C, Suárez A, Macaya CLong-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. <i>J Am Coll Cardiol 2008 Nov 11;52:1621-7</i> [PMID 18992651] </p>